

U.S.S.N. 09/038,894  
STOUGHTON *et al.*  
Preliminary Amendm nt

at page 146, line 31, in "thatwould", insert a space between "that" and "would";

at page 153, line 9, replace "nacceptable" with —unacceptable—;

at page 165, line 2, replace the apostrophes around "primed" with quotation marks;

at page 165, line 15, replace the apostrophes around "Preactivation" with quotation marks;

at page 166, line 17, insert a space between "intake" and "can";

at page 166, line 20, replace the apostrophes around "preactivation" with quotation marks;

at page 166, line 26, replace "exhitibs" with —exhibits—;

**IN THE CLAIMS:**

Please cancel claim 37 without prejudice or disclaimer.

Please amend claims 17, 20, 30, 31, 35 and 36 as follows:

aa1 17. The method of claim 10, wherein the [disorder] disease or condition is selected from the group consisting of myocardial infarction, stroke, hemorrhagic shock, diabetic retinopathy, diabetes, and venous insufficiency.

aa2 20. The method of claim 19, wherein the protease inhibitor is a serine protease inhibitor.

aa3 30. The method of claim [28] 29, wherein the cells are endothelial cells.

31. The method of claim [28] 29, wherein the cells are contacted with the composition prior to contacting the cells with the compound.

35. The method of claim [32] 34, wherein the protease inhibitor is a serine protease inhibitor.

aa4 36. The method of claim [32] 34, wherein the protease inhibitor is selected from among  $\alpha_1$ -proteinase inhibitor ( $\alpha_1$ -antitrypsin),  $\alpha_2$ -macroglobin, inter- $\alpha_1$ -trypsin inhibitor, and  $\alpha_1$ -antichymotrypsin.